Manhattan Scientifics Inc (MHTX)

[rustydog62]

And from the collaboration agreement between PAB and IBX signed 6 months ago...

Dr. James Campbell, Patrys’ CEO and Managing Director. “The potential for our deoxymab antibodies to home in on a range of different cancer types due to their affinity for DNA is one of the properties that makes them so unique and opens up a range of different clinical applications for their use. We are very excited to be further leveraging the cancer-targeting ability of deoxymabs by partnering with Imagion and its innovative MagSense® imaging technology to potentially develop new ways to visualise and diagnose cancer. This is the first of multiple potential applications of our deoxymab platform, and while our focus is on advancing our novel cancer therapeutics to the clinic we are actively engaged in business development efforts for the broader platform to leverage theunique attributes of deoxymabs.”